VASH Inhibitors with Enhanced Specificity and Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current VASH inhibitors, such as EPO-Y and parthenolide, exhibit moderate specificity and potency issues, leading to non-specific interactions with other proteins and enzymes, limiting their effectiveness in treating disorders related to microtubule detyrosination.
Innovation Solution
Development of new VASH inhibitors with enhanced in vitro and in cellulo activity, specifically designed using medicinal chemistry and bioinformatics to improve structural properties, resulting in compounds with picomolar to nanomolar potency, as represented by the formula (I), which are used alone or in conjunction with pharmaceutically acceptable salts and solvates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing VASH inhibitors (EPO-Y, parthenolide) are used, then some inhibitory activity is achieved, but specificity and potency are moderate, leading to non-specific interactions with other proteins and enzymes
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of VASH inhibitors to achieve picomolar to nanomolar potency. The compounds of formula (I) feature specific structural parameters (R1-R6, X, Y groups) that are optimized to enhance binding affinity and specificity for VASH peptidase, thereby reducing non-specific interactions with other proteins and enzymes while maintaining reliable inhibitory activity.
2Reliability
If existing VASH inhibitors are used, then some inhibitory activity is achieved, but potency is moderate (micromolar range), limiting effectiveness in treating disorders
Solution Approach 1:
The patent employs parameter changes to transform the potency of VASH inhibitors from micromolar range to picomolar to nanomolar range. The compounds of formula (I) incorporate specifically designed molecular parameters (R1-R6 substituents, X and Y groups) that optimize the interaction with VASH peptidase active site, dramatically enhancing potency and thereby improving effectiveness in treating neurodegenerative diseases and other disorders.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new VASH inhibitors demonstrate significantly improved specificity and potency, effectively inhibiting VASH peptidase activity, potentially offering more effective treatments for neurodegenerative diseases and other disorders associated with microtubule detyrosination.
Implementation Method 1
The new VASH inhibitors demonstrate significantly improved specificity and potency, effectively inhibiting VASH peptidase activity
Data Source
AI summary
The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.